Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term InvestmentsNon-Current AssetsOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Lyell Immunopharma (LYEL) Long-Term Investments (2020 - 2025)

Historic Long-Term Investments for Lyell Immunopharma (LYEL) over the last 6 years, with Q3 2025 value amounting to $19.0 million.

  • Lyell Immunopharma's Long-Term Investments fell 552.9% to $19.0 million in Q3 2025 from the same period last year, while for Sep 2025 it was $19.0 million, marking a year-over-year decrease of 552.9%. This contributed to the annual value of $19.0 million for FY2024, which is 4062.69% down from last year.
  • Latest data reveals that Lyell Immunopharma reported Long-Term Investments of $19.0 million as of Q3 2025, which was down 552.9% from $20.1 million recorded in Q2 2025.
  • Over the past 5 years, Lyell Immunopharma's Long-Term Investments peaked at $317.5 million during Q3 2021, and registered a low of $10.0 million during Q1 2023.
  • For the 5-year period, Lyell Immunopharma's Long-Term Investments averaged around $85.3 million, with its median value being $32.0 million (2023).
  • Per our database at Business Quant, Lyell Immunopharma's Long-Term Investments soared by 23976.97% in 2021 and then tumbled by 9553.81% in 2023.
  • Over the past 5 years, Lyell Immunopharma's Long-Term Investments (Quarter) stood at $283.5 million in 2021, then tumbled by 75.27% to $70.1 million in 2022, then crashed by 54.36% to $32.0 million in 2023, then plummeted by 40.63% to $19.0 million in 2024, then changed by 0.0% to $19.0 million in 2025.
  • Its Long-Term Investments stands at $19.0 million for Q3 2025, versus $20.1 million for Q2 2025 and $28.9 million for Q1 2025.